Fianlimab (Not yet branded)
Immunotherapy
Description
Fianlimab is a monoclonal antibody immunotherapy agent that targets the LAG-3 (Lymphocyte Activation Gene-3) immune checkpoint receptor. In colorectal cancer treatment, fianlimab is being evaluated in combination with cemiplimab (anti-PD-1 antibody) for patients with both microsatellite instability-high (MSI-H) and microsatellite stable (MSS) tumors. The combination approach aims to enhance anti-tumor immune responses in patients with localized, locally advanced, and resectable non-metastatic colorectal cancer.
Mechanism of Action
Fianlimab blocks the LAG-3 receptor, which is an inhibitory checkpoint protein expressed on activated T cells and other immune cells. By inhibiting LAG-3, fianlimab prevents the suppression of T cell activation and proliferation, thereby enhancing the body's immune response against cancer cells. When combined with PD-1 inhibitors like cemiplimab, this dual checkpoint blockade can provide synergistic anti-tumor activity by targeting multiple immune suppressive pathways.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Immunotherapy |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 4 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.